Mean HBsAg reduction of -1.9 Log10 (-98.7%) with a range of -1.3 Log10 (-95.0%) to -3.8 Log10 (-99.98%) - ARO-HBV appears to be well-tolerated at monthly doses up to 400 mg.
http://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-presents-late-breaking-preliminary